Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy,and despite advancements in therapeutics,most women unfortunately still succumb to their disease.Immunotherapies,in particular immune checkpoi...Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy,and despite advancements in therapeutics,most women unfortunately still succumb to their disease.Immunotherapies,in particular immune checkpoint inhibitors(ICI),have been therapeutically transformative in many tumour types,including gynaecological malignancies such as cervical and endometrial cancer.Unfortunately,these therapeutic successes have not been mirrored in ovarian cancer clinical studies.This review provides an overview of the ovarian tumour microenvironment(TME),particularly factors associated with survival,and explores current research into immunotherapeutic strategies in EOC,with an exploratory focus on novel therapeutics in navigating drug resistance.展开更多
基金LK has been supported by postgraduate scholarships from the Australian Government(National Health and Medical Research Council,2022/2021964)Sydney Cancer Partners(Cancer Institute New South Wales,2021/CBG0002).
文摘Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy,and despite advancements in therapeutics,most women unfortunately still succumb to their disease.Immunotherapies,in particular immune checkpoint inhibitors(ICI),have been therapeutically transformative in many tumour types,including gynaecological malignancies such as cervical and endometrial cancer.Unfortunately,these therapeutic successes have not been mirrored in ovarian cancer clinical studies.This review provides an overview of the ovarian tumour microenvironment(TME),particularly factors associated with survival,and explores current research into immunotherapeutic strategies in EOC,with an exploratory focus on novel therapeutics in navigating drug resistance.
